Evidence map›Paper›PMID 39452711›Full record

ArticlePathogens (Basel, Switzerland)2024

A New Approach for Phage Cocktail Design in the Example of Anti-Mastitis Solution.

Daria Królikowska, Marta Szymańska, Marta Krzyżaniak, Arkadiusz Guziński, Rafał Matusiak, Agnieszka Kajdanek, Edyta Kaczorek-Łukowska, Agnieszka Maszewska, Ewelina A Wójcik, Jarosław Dastych

Abstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daria KrólikowskaProteon Pharmaceuticals, Tylna 3a, 90-364 Łódź, Poland.ORCID 0009-0004-2623-7628
Marta SzymańskaProteon Pharmaceuticals, Tylna 3a, 90-364 Łódź, Poland.
Marta KrzyżaniakProteon Pharmaceuticals, Tylna 3a, 90-364 Łódź, Poland.
Arkadiusz GuzińskiProteon Pharmaceuticals, Tylna 3a, 90-364 Łódź, Poland.
Rafał MatusiakProteon Pharmaceuticals, Tylna 3a, 90-364 Łódź, Poland.ORCID 0000-0002-2796-610X
Agnieszka KajdanekProteon Pharmaceuticals, Tylna 3a, 90-364 Łódź, Poland.ORCID 0009-0006-7265-331X
Edyta Kaczorek-ŁukowskaDepartment of Microbiology and Clinical Immunology, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 13, 10-719 Olsztyn, Poland.ORCID 0000-0002-9962-0917
Agnieszka MaszewskaProteon Pharmaceuticals, Tylna 3a, 90-364 Łódź, Poland.
Ewelina A WójcikProteon Pharmaceuticals, Tylna 3a, 90-364 Łódź, Poland.ORCID 0000-0002-9743-9268
Jarosław DastychProteon Pharmaceuticals, Tylna 3a, 90-364 Łódź, Poland.

Funding

European Regional Development Fund and the state budget, "Smart Growth Operational Program 2014-2020 Project no POIR.01.01.01-00-0016/16 "Bacteriophage preparation for the treatment of mastitis in cows caused by antibiotic-resistant bacteria"
6 · The paper itself

Abstract

The studies on phage therapy have shown an overall protective effect of phages in bacterial infections, thus providing an optimistic outlook on the future benefits of phage-based technologies for treating bacterial diseases. However, the therapeutic effect is highly affected by the proper composition of phage cocktails. The rational approach to the design of bacteriophage cocktails, which is the subject of this study, allowed for development of an effective anti-mastitis solution, composed of virulent bacteriophages acting on

Indexed as

BacteriophagesBiofilmsEscherichia coliPhage TherapyStaphylococcus aureusAnimalsCattleEscherichia coli InfectionsFemaleMilkStaphylococcal InfectionsStaphylococcus Phagesantibiotic resistancebacteriophage therapybiofilmbioinformatics-based designmastitismilk modelstructural analyses of phages

Identifiers

PMID39452711
PMCPMC11510089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.